Research letterImmunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts
Key words
atopic dermatitis
autoimmune diseases
biologics
COVID-19
IL-4A
IL-12/22
IL-17A
psoriasis
systemic immunosuppression
systemic lupus erythematosus
TNF
Cited by (0)
Drs Pahalyants and Murphy are cofirst authors.
IRB approval status: Approved by the institutional review boards of Mass General Brigham (Protocol 2020P001191) and Massachusetts Department of Public Health (Protocol 1606024-2).
Funding sources: None.
© 2021 by the American Academy of Dermatology, Inc.